Select Page

South Delhi Pharma, New Delhi, India

KADCYLA™ (ado-trastuzumab emtansine) for injection

SDP are here to serve you through the quality pharmaceutical products as per your needs. Established in the year 1996, we have earned a global reputation in the market. Owing to superior quality widest range of Anti Cancer medicines.

ado-trastuzumab emtansine
In the United States, ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

9 + 5 =

INDICATIONS
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
 Received prior therapy for metastatic disease, or
 Developed disease recurrence during or within six months of
completing adjuvant therapy.

DOSAGE FORMS AND STRENGTHS
Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.

Reviews

There are no reviews yet.

Be the first to review “KADCYLA™ (ado-trastuzumab emtansine) for injection”

Your email address will not be published. Required fields are marked *